• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Best and Worst US Cities for Patients with Seasonal Allergies

Article

With allergy season already here, the Asthma and Allergy Foundation of America (AAFA) recently released its annual Allergy Capitals™ report for 2021. The report identifies the most challenging cities for seasonal allergic rhinitis (ie, hay fever) in the top 100 US metropolitan areas. Cities are graded on 3 factors: Spring and fall pollen scores, over-the-counter medicine use, and availability of board-certified allergists. For each factor, the AAFA used the most recently available 12-month data.

In the slides below, find out which areas ranked most and least challenging for patients with seasonal allergies.

Related Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
Tezepelumab Effective in Severe Asthma Cohorts Stratified by Age at Onset, Inflammatory Phenotype, and Allergen Sensitization

Tezepelumab Effective in Severe Asthma Cohorts Stratified by Age at Onset, Inflammatory Phenotype, and Allergen Sensitization

February 24th 2023
Article

AAAAI 2023. The TSLP inhibitor was superior to placebo in 2 post hoc analyses of the PATHWAY and NAVIGATOR clinical trials.

Fluticasone Exhalation Delivery System Reduced Exacerbations, Need for Antibiotics in Patients with Chronic Sinusitis

Fluticasone Exhalation Delivery System Reduced Exacerbations, Need for Antibiotics in Patients with Chronic Sinusitis

October 24th 2022
Article

IDWeek 2022: New data show a greater than 60% reduction in acute exacerbations and need for antibiotics in patients with CS who used fluticasone propionate nasal spray.

Chronic Sinusitis Flares Reduced by 66% in Pooled Analysis of Optinose ReOpen Program Data

Chronic Sinusitis Flares Reduced by 66% in Pooled Analysis of Optinose ReOpen Program Data

July 13th 2022
Article

For patients with chronic sinusitis, disease exacerbations often require use of antibiotics and steroids, in addition to medical office visits, all of which impact quality of life.

FDA Approved Dupilumab as the First Treatment for Eosinophilic Esophagitis

FDA Approved Dupilumab as the First Treatment for Eosinophilic Esophagitis

May 23rd 2022
Article

Dupilumab is approved for the treatment of eosinophilic esophagitis in patients aged ≥12 years weighing at least 40 kgs.

Tezepelumab for Severe Asthma Halves Exacerbation Rates Across Respiratory Comorbidities

Novel Agent for Severe Asthma Halves Exacerbation Rates Across Respiratory Comorbidities

February 28th 2022
Article

Tezepelumab, a TSLP inhibitor, reduced asthma exacerbation rates in patients with severe uncontrolled disease across a range of respiratory comorbidities.

chronic hives, chronic Spontaneous Urticaria

Dupilumab Significantly Decreased Itch and Hives in Patients with Chronic Spontaneous Urticaria

February 26th 2022
Article

Dupilumab significantly reduced itch and hives in patients with H1 antihistamine-resistant chronic spontaneous urticaria, according to new research.

© 2023 MJH Life Sciences

All rights reserved.